Published in Medical Devices and Surgical Technology Week, July 13th, 2003
Gelclair is a bioadherent oral gel that provides relief for the treatment of pain associated with oral mucositis, a debilitating side effect often seen in cancer patients undergoing radiation treatment or chemotherapy. Previously, Gelclair was marketed to oncologists for their cancer patients under a copromotion agreement between Celgene and Cell Pathways, Inc. Gelclair was added to OSI's oncology portfolio as part of the company's recent acquisition of Cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.